Insider Deck research · News

NUVB stock news · Nuvation Bio Inc.

Latest Nuvation Bio Inc. (NUVB) stock news, headlines, and research context on Insider Deck. Market cap $2.2B.

News desk

Nuvation Bio Inc. wire

Read the briefing on Insider Deck — headline, teaser, and desk context stay here. Publisher sites remain optional for the full longform.

10 on the wireUpdated within the hour

Simply Wall St.·Tue, Aug 4, 4:16 PM

Do IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy?

Nuvation Bio Inc. announced that new long-term analyses from its pivotal Phase 2 TRUST-I and TRUST-II trials of IBTROZI (taletrectinib) in adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, originally scheduled for presentation at WCLC and ESMO in 2026, were subsequently presented and posted on its website. The upcoming detailed subgroup efficacy and safety readouts for IBTROZI, building on its June 2025 US FDA approval, give investors additional...

Insider Deck desk note

Last$6.37
Day-1.09%
SymbolNUVB

Cross-check the tape against filings and ownership — the headline is the spark; the desk is the research.

Company KPIsShareholdersBuys vs Sells
Continue on Simply Wall St.

Frequently asked questions

What is the latest news on NUVB?

The NUVB news desk aggregates recent headlines with research context for Nuvation Bio Inc..

Where can I research NUVB on Insider Deck?

Nuvation Bio Inc. (NUVB) research covers KPIs, earnings, fundamentals, institutional ownership, 13F flow, news, and DCF valuation.